MDD
MCID: DPR016
MIFTS: 73

Depression (MDD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Depression

MalaCards integrated aliases for Depression:

Name: Depression 25 29 43 63
Depressive Disorder 25 55 73
Major Depressive Disorder 25 73
Unipolar Depression 25 73
Clinical Depression 25 73
Depressive Syndrome 55 73
Major Depression 25 55
Mental Depression 73
Mdd 25

Classifications:



Summaries for Depression

MedlinePlus : 43 Depression is a serious medical illness. It's more than just a feeling of being sad or "blue" for a few days. If you are one of the more than 19 million teens and adults in the United States who have depression, the feelings do not go away. They persist and interfere with your everyday life. Symptoms can include Feeling sad or "empty" Loss of interest in favorite activities Overeating, or not wanting to eat at all Not being able to sleep, or sleeping too much Feeling very tired Feeling hopeless, irritable, anxious, or guilty Aches or pains, headaches, cramps, or digestive problems Thoughts of death or suicide Depression is a disorder of the brain. There are a variety of causes, including genetic, biological, environmental, and psychological factors. Depression can happen at any age, but it often begins in teens and young adults. It is much more common in women. Women can also get postpartum depression after the birth of a baby. Some people get seasonal affective disorder in the winter. Depression is one part of bipolar disorder. There are effective treatments for depression, including antidepressants, talk therapy, or both. NIH: National Institute of Mental Health

MalaCards based summary : Depression, also known as depressive disorder, is related to postpartum depression and atypical depressive disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Depression is BDNF-AS (BDNF Antisense RNA), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Genetics Home Reference : 25 Depression (also known as major depression or major depressive disorder) is a psychiatric disorder that affects mood, behavior, and overall health. It causes prolonged feelings of sadness, emptiness, or hopelessness, and a loss of interest in activities that were once enjoyed. People with depression may also have changes in appetite (leading to overeating or not eating enough), changes in sleeping patterns (sleeping too much or not being able to sleep), loss of energy, and difficulty concentrating. Although depression is considered primarily a mental health disorder, it can also have physical features including headaches, other unexplained aches and pains, unusually slow or fast movements, and digestive problems. To be diagnosed with depression, an individual must have signs and symptoms nearly every day for at least 2 weeks. However, the features of this condition vary widely.

PubMed Health : 63 About depression: We all feel sad or lethargic every now and then. And we have all felt down or even desperate at some point in our lives. These phases are a normal part of life, and people usually feel better again after a while. Things are different for people who have depression. Their sadness and negative thoughts last longer and overshadow all of their thoughts and actions. Depression can arise without any triggering events or for no apparent reasons. People often feel like they are stuck in a black hole. They feel cheerless, lack motivation and self-confidence, and think of themselves as worthless. This can make it difficult to do everyday things like going to work or studying. Friends, family and hobbies are often neglected. They don't sleep well.Depression can also make family and friends feel worried, anxious and helpless. Often they want to help but don't know how. It's not always easy for them to tell whether it's a passing phase or a serious illness.

Related Diseases for Depression

Diseases related to Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1321)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 34.1 BDNF CRH MAOA SLC6A4
2 atypical depressive disorder 34.0 CRH HTR2A MAOA SLC6A4
3 endogenous depression 33.9 BDNF CRH CRHR1 HTR1A HTR2A MAOA
4 major depressive disorder 33.8 BDNF CRH CRHR1 DISC2 HTR1A HTR2A
5 mental depression 33.4 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
6 dysthymic disorder 32.4 HTR2A MAOA SLC6A4
7 eating disorder 32.1 BDNF CRH HTR2C SLC6A4
8 anxiety 32.1 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
9 schizoaffective disorder 32.1 BDNF DISC2 HTR2A SLC6A4
10 fibromyalgia 32.1 CRH HTR2A SLC6A4
11 irritable bowel syndrome 32.0 CRH CRHR1 SLC6A4
12 bulimia nervosa 32.0 BDNF HTR2A SLC6A4
13 bipolar i disorder 31.9 BDNF HTR1A HTR2A HTR2C SLC6A4
14 parkinson disease, late-onset 31.8 BDNF HTR1A HTR2A MAOA NOS1 SLC6A4
15 migraine with or without aura 1 31.8 HTR1A HTR2A HTR2C MAOA SLC6A4
16 borderline personality disorder 31.7 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
17 bipolar disorder 31.7 BDNF CRH DISC2 GRIA1 GRIA3 GRM1
18 mood disorder 31.4 BDNF CRH CRHR1 DISC2 HTR1A HTR2A
19 autism spectrum disorder 31.4 BDNF DISC2 HTR2A RELN SLC6A4 TPH2
20 personality disorder 30.8 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
21 alcohol abuse 30.8 BDNF HTR2A SLC6A4
22 post-traumatic stress disorder 30.8 BDNF CRH HTR2A MAOA SLC6A4
23 generalized anxiety disorder 30.8 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
24 substance abuse 30.7 BDNF MAOA SLC6A4
25 social phobia 30.6 HTR1A MAOA SLC6A4
26 sexual disorder 30.6 HTR1A NOS1 SLC6A4
27 agoraphobia 30.5 HTR1A MAOA SLC6A4
28 tobacco addiction 30.5 HTR2A MAOA SLC6A4
29 anorexia nervosa 30.5 BDNF CRH HTR2A SLC6A4
30 substance dependence 30.4 BDNF MAOA SLC6A4
31 obsessive-compulsive disorder 30.4 BDNF CRH HTR1A HTR2A HTR2C MAOA
32 chronic fatigue syndrome 30.4 CRH HTR1A HTR2A MAOA SLC6A4 TPH2
33 panic disorder 30.4 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
34 alcohol dependence 30.3 BDNF CRHR1 HTR1A HTR2A HTR2C MAOA
35 attention deficit-hyperactivity disorder 30.3 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
36 drug dependence 30.3 BDNF CRH SLC6A4
37 oppositional defiant disorder 30.2 MAOA SLC6A4 TPH2
38 temporal lobe epilepsy 30.1 BDNF HTR1A RELN
39 autism 30.1 BDNF HTR1A HTR2A MAOA RELN SLC6A4
40 paranoid schizophrenia 30.1 BDNF HTR2A MAOA SLC6A4 TPH2
41 pathological gambling 30.1 HTR2A MAOA SLC6A4
42 premature ejaculation 30.0 HTR1A HTR2C SLC6A4
43 serotonin syndrome 29.9 HTR1A HTR2A MAOA SLC6A4
44 fragile x syndrome 29.9 BDNF GRIA1 GRM1 SLC6A4
45 kleptomania 29.8 HTR1A MAOA SLC6A4
46 schizophrenia 29.8 BDNF BDNF-AS DISC2 GRIA1 GRIA2 GRIA3
47 psychotic disorder 29.8 BDNF HTR1A HTR2A HTR2C NOS1 RELN
48 status epilepticus 29.7 BDNF GRIA1 GRIA2
49 hypoactive sexual desire disorder 29.6 HTR1A HTR2A
50 early-onset schizophrenia 29.6 BDNF HTR2A

Graphical network of the top 20 diseases related to Depression:



Diseases related to Depression

Symptoms & Phenotypes for Depression

UMLS symptoms related to Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

MGI Mouse Phenotypes related to Depression:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
2 homeostasis/metabolism MP:0005376 10.25 BDNF CRH CRHR1 GRIA1 GRIA2 GRID2
3 growth/size/body region MP:0005378 10.23 BDNF CRH GRIA1 GRIA2 GRIA3 GRID2
4 nervous system MP:0003631 10.19 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
5 mortality/aging MP:0010768 10.18 BDNF CRHR1 GRIA2 GRIA3 GRID2 GRM1
6 integument MP:0010771 10.1 BDNF CRH GRIA1 GRIA2 GRIA3 GRM1
7 muscle MP:0005369 9.92 GRID2 GRM1 HTR2A HTR2C NOS1 PDLIM5
8 no phenotypic analysis MP:0003012 9.85 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
9 normal MP:0002873 9.56 BDNF CRH CRHR1 GRIA1 GRIA2 NOS1
10 reproductive system MP:0005389 9.28 BDNF GRIA2 GRIA3 GRID2 GRM1 NOS1

Drugs & Therapeutics for Depression

PubMedHealth treatment related to Depression: 63

Many people who have depression find it hard to accept that fact. One possible reason for this is that they are ashamed about having a mental health problem and don't want their friends, family and colleagues to find out. Some people don't want to have treatment as a result. But treatment can often shorten depressive episodes and relieve people's symptoms.There are various treatment options for depression. The main treatments are psychological treatment, such as cognitive behavioral therapy, and/or medication. Which type of treatment is the most appropriate, where it should take place and how long it lasts will depend on several factors, including how severe the person’s depression is, their personal circumstances, and how their symptoms develop over time. People can talk to a therapist about the advantages and disadvantages of the possible treatments, as well as what they expect from treatment and any fears they might have.

Drugs for Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
4
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
5
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 34841-39-9, 34911-55-2 444
6
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
7
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
8
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68-41-7 6234 401
9
Clonazepam Approved, Illicit Phase 4,Phase 2,Early Phase 1,Not Applicable 1622-61-3 2802
10
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 91374-21-9, 91374-20-8 497540 5095
11
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
12
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
13
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54739-18-3 3404 5324346
14
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
15
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
16
Angiotensin II Approved, Investigational Phase 4,Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
17
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
18
Etomidate Approved Phase 4,Not Applicable 33125-97-2 667484 36339
19
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24219-97-4 4184
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
21
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61337-67-5, 85650-52-8 4205
22
Reboxetine Approved, Experimental Phase 4,Phase 2,Not Applicable 98769-81-4, 71620-89-8 123628 65856
23
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
24
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-03-3
25
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 19794-93-5 5533
26 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
27
Copper Approved, Investigational Phase 4,Phase 3 7440-50-8 27099
28
Norethindrone Approved Phase 4 68-22-4 6230
29
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
30
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 1,Not Applicable 57-63-6 5991
31
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
32
Eszopiclone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 138729-47-2 969472
33
Buspirone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 36505-84-7 2477
34
Promethazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-87-7 4927
35
Diphenhydramine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
36
Suvorexant Approved, Investigational Phase 4 1030377-33-3
37
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
38
Nortriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72-69-5 4543
39
Trimipramine Approved Phase 4 739-71-9 5584 4055
40
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
41
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
42
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 508233-74-7 9966051
43
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
44
Methimazole Approved Phase 4 60-56-0 1349907
45
Lactulose Approved Phase 4 4618-18-2 11333
46
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
47
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-22-0 6013
48
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-18-4 6010
49
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Not Applicable 315-37-7 9416
50
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5949-44-0

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
2 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
3 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
4 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
5 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
6 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
7 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
8 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
9 Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine Unknown status NCT02989727 Phase 4 Lamotrigine;Placebos
10 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
11 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
12 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
13 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
14 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
15 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
16 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
17 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
18 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
19 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
20 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
21 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
22 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
23 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
24 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
25 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
26 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
27 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
28 Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
29 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
30 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
31 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
32 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
33 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
34 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
35 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
36 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
37 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
38 Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
39 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
40 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
41 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
42 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
43 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
44 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
45 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
46 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
47 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
48 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
49 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
50 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine

Search NIH Clinical Center for Depression

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Depression

Genetic tests related to Depression:

# Genetic test Affiliating Genes
1 Depression 29

Anatomical Context for Depression

MalaCards organs/tissues related to Depression:

41
Brain, Breast, Heart, Testes, Lung, Cortex, Spinal Cord

Publications for Depression

Articles related to Depression:

(show top 50) (show all 13574)
# Title Authors Year
1
Corrigendum to "The development and validation of Huaxi emotional-distress index (HEI): A Chinese questionnaire for screening depression and anxiety in non-psychiatric clinical settings" [Compr. Psychiatry 76 (2017) 87-97]. ( 30501894 )
2019
2
Substance use outcomes in cocaine-dependent tobacco smokers: A mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression. ( 30466549 )
2019
3
Predicting treatment outcome for anxiety disorders with or without comorbid depression using clinical, imaging and (epi)genetic data. ( 30480619 )
2019
4
Exposure to nanoscale diesel exhaust particles: Oxidative stress, neuroinflammation, anxiety and depression on adult male mice. ( 30391838 )
2019
5
Effect of fluoride exposure on anxiety- and depression-like behavior in mouse. ( 30336322 )
2019
6
Prevalence of and factors contributing to anxiety, depression and cognitive disorders among urban elderly in Odisha - A study through the health systems' Lens. ( 30336373 )
2019
7
Relations between trait anxiety and depression: A mediated moderation model. ( 30359817 )
2019
8
Evaluating the role of mindfulness in terms of asthma-related outcomes and depression and anxiety symptoms among individuals with asthma. ( 30286606 )
2019
9
Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. ( 30292023 )
2019
10
Symptoms of social anxiety disorder and major depressive disorder: A network perspective. ( 30292147 )
2019
11
Cooperation of the vestibular and cerebellar networks in anxiety disorders and depression. ( 30292730 )
2019
12
A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. ( 30293440 )
2019
13
Anxiety and depression among adult amputees: the role of attachment insecurity, coping strategies and social support. ( 30299156 )
2019
14
Appraisals of dependent stressor controllability and severity are associated with depression and anxiety symptoms in youth. ( 30303017 )
2019
15
Interrelationships among depression, anxiety, flourishing, and cannabis use in youth. ( 30321693 )
2019
16
Neuroticism and extraversion mediate the relationship between having a sibling with developmental disabilities and anxiety and depression symptoms. ( 30248634 )
2019
17
Affective models of depression and anxiety: Extension to within-person processes in daily life. ( 30248635 )
2019
18
Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. ( 30248637 )
2019
19
A randomized controlled trial of 'MUMentum Pregnancy': Internet-delivered cognitive behavioral therapy program for antenatal anxiety and depression. ( 30266030 )
2019
20
Psychosocial factors associated with symptoms of depression, anxiety and stress among single mothers with young children: A population-based study. ( 30218920 )
2019
21
High risk of depression, anxiety, and poor quality of life among experienced fathers, but not mothers: A prospective longitudinal study. ( 30170237 )
2019
22
The moderating role of social support for marital adjustment, depression, anxiety, and stress: Evidence from Pakistani working and nonworking women. ( 30173879 )
2019
23
Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression? ( 30176494 )
2019
24
Corrigendum to "Taxonicity and network structure of generalized anxiety disorder and major depressive disorder: An admixture analysis and complex network analysis." [Journal of Affective Disorders, 199 (2016) 99-105]. ( 30189353 )
2019
25
The prevalence of depression and insomnia symptoms among patients with rheumatoid arthritis and osteoarthritis in Poland: a case control study. ( 30286609 )
2019
26
Associations between broader autism phenotype (BAP) and maternal attachment are moderated by maternal postpartum depression when infants are one month old: A prospective study of the Japan environment & children's study. ( 30273887 )
2019
27
Depression enhanced the production of autoantibodies against 16α‑hydroxyestrone-estrogen receptor adduct in breast cancer. ( 30500622 )
2019
28
Adolescent Depression: National Trends, Risk Factors, and Healthcare Disparities. ( 30522576 )
2019
29
Financial Distress and Smoking-induced Deprivation in Smokers with Depression. ( 30522579 )
2019
30
Training health visitors in cognitive behavioural or person-centred approaches is cost-effective and can improve outcomes for women at risk of postnatal depression. ( 30530764 )
2019
31
Structural and functional damage to the hippocampal neurovascular unit in diabetes-related depression. ( 30531012 )
2019
32
Predator stress-induced depression is associated with inhibition of hippocampal neurogenesis in adult male mice. ( 30531013 )
2019
33
Implementing and feasibility testing depression screening using the electronic medical record for patients with type 2 diabetes admitted to the hospital. ( 30534392 )
2019
34
The Forced Swim Test for Depression-Like Behavior in Rodents. ( 30535683 )
2019
35
Impact of New-Onset Postoperative Depression on Readmission Outcomes After Surgical Coronary Revascularization. ( 30502287 )
2019
36
The role of knowledge in internet-based cognitive behavioural therapy for adolescent depression: Results from a randomised controlled study. ( 30519531 )
2019
37
Brain arousal regulation in SSRI-medicated patients with major depression. ( 30448695 )
2019
38
Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients. ( 30408786 )
2019
39
Comparison of treatment options for depression in heart failure: A network meta-analysis. ( 30419488 )
2019
40
Transcranial Magnetic Stimulation for Adolescent Depression. ( 30389074 )
2019
41
Inflammation as a predictor of disease course in posttraumatic stress disorder and depression: A prospective analysis from the Mind Your Heart Study. ( 30389462 )
2019
42
Ketamine and depression: A special kase for kynurenic acid? ( 30399405 )
2019
43
The areas of life dissatisfaction and their relationships to depression at different life stages: findings from a nationally representative survey. ( 30345809 )
2019
44
Peripheral blood E2F1 mRNA in depression and following electroconvulsive therapy. ( 30365982 )
2019
45
Ruminative response style is associated with a negative bias in the perception of emotional facial expressions in healthy women without a history of clinical depression. ( 30366227 )
2019
46
Risk Factors for Post-Acute Coronary Syndrome Depression: A Meta-analysis of Observational Studies. ( 30312193 )
2019
47
Disentangling the association of depression on the anti-fatigue effects of ketamine. ( 30312839 )
2019
48
The relationship between Internet Use Disorder, depression and burnout among Chinese and German college students. ( 30321691 )
2019
49
Effect of self-monitoring through experience sampling on emotion differentiation in depression. ( 30321767 )
2019
50
Transcranial Magnetic Stimulation in Conditions Other than Major Depressive Disorder. ( 30389075 )
2019

Variations for Depression

Expression for Depression

Search GEO for disease gene expression data for Depression.

Pathways for Depression

Pathways related to Depression according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 CRH CRHR1 GRIA1 GRIA2 GRIA3 GRID2
2
Show member pathways
13.19 BDNF GRIA1 GRIA2 GRIA3 GRID2 GRM1
3
Show member pathways
12.96 GRIA1 GRIA2 GRIA3 GRM1 MAOA NOS1
4
Show member pathways
12.96 BDNF CRH CRHR1 GRM1 HTR2A HTR2C
5
Show member pathways
12.86 GRIA1 GRIA2 GRIA3 GRM1 MAOA PDLIM5
6
Show member pathways
12.56 BDNF GRIA1 GRIA2 GRIA3 GRM1 NOS1
7
Show member pathways
12.45 GRIA1 GRIA2 GRIA3 GRM1
8 12.29 GRIA1 GRIA2 GRIA3 GRM1 HTR1A NOS1
9 12.27 GRIA1 GRIA2 GRIA3 NOS1
10
Show member pathways
12.21 BDNF GRIA1 GRIA2 GRIA3 HTR1A
11
Show member pathways
12.17 GRM1 HTR2A HTR2C NOS1
12
Show member pathways
12.11 GRIA1 GRIA2 GRIA3 GRM1
13 12.04 BDNF GRIA1 GRIA2 GRIA3
14 12.01 BDNF HTR1A HTR2A MAOA SLC6A4 TPH2
15
Show member pathways
11.98 GRIA1 GRIA3 GRM1 PDLIM5
16 11.93 GRIA2 GRIA3 HTR1A
17
Show member pathways